OmniAb Reports Strong Q1 2026 Performance, Raises Revenue Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy OABI?
Source: seekingalpha
- Significant Revenue Growth: OmniAb reported total revenue of $14.4 million for Q1 2026, exceeding expectations by $8.8 million, reflecting strong progress in partner programs that is expected to drive future milestones and new royalty income.
- Expanded Partner Base: As of the end of Q1, OmniAb had 107 active partners and 409 active programs, with total contracted milestones exceeding $3 billion and an average royalty rate of approximately 3.4%, laying a solid foundation for future revenue diversification.
- Upgraded Financial Outlook: The company raised its total revenue guidance for 2026 to a range of $28 million to $33 million, primarily driven by a milestone achieved by a partner that was not included in the original guidance, while maintaining cash operating expense expectations unchanged at $50 million to $55 million.
- Ongoing Clinical Progress: By the end of Q1, OmniAb had 32 active clinical programs, with Ramantamig advancing from Phase I to Phase III, demonstrating strong development potential in the clinical stage and further enhancing market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OABI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OABI
Wall Street analysts forecast OABI stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.430
Low
3.00
Averages
6.80
High
11.00
Current: 1.430
Low
3.00
Averages
6.80
High
11.00
About OABI
OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OmniAb Reports Strong Q1 2026 Performance, Raises Revenue Guidance
- Significant Revenue Growth: OmniAb reported total revenue of $14.4 million for Q1 2026, exceeding expectations by $8.8 million, reflecting strong progress in partner programs that is expected to drive future milestones and new royalty income.
- Expanded Partner Base: As of the end of Q1, OmniAb had 107 active partners and 409 active programs, with total contracted milestones exceeding $3 billion and an average royalty rate of approximately 3.4%, laying a solid foundation for future revenue diversification.
- Upgraded Financial Outlook: The company raised its total revenue guidance for 2026 to a range of $28 million to $33 million, primarily driven by a milestone achieved by a partner that was not included in the original guidance, while maintaining cash operating expense expectations unchanged at $50 million to $55 million.
- Ongoing Clinical Progress: By the end of Q1, OmniAb had 32 active clinical programs, with Ramantamig advancing from Phase I to Phase III, demonstrating strong development potential in the clinical stage and further enhancing market competitiveness.
See More
OmniAb (OABI) Q4 2025 Earnings Call Transcript
See More
OmniAb Q4 2025 Earnings Call Highlights
- Partner Growth: By the end of 2025, OmniAb had 107 partners and 407 active programs, reflecting a net increase of 44 programs compared to 2024, demonstrating the company's ongoing expansion in its partner base and program portfolio, despite a decline in overall revenue, laying a foundation for sustained future growth.
- Innovation Platform Launch: OmniUltra, the industry's first transgenic chicken platform, was launched in December 2025, aimed at driving new partner additions and program starts, expected to generate near-term revenue opportunities and extend into peptide discovery applications.
- Financial Performance: Total revenue for 2025 was $18.4 million, down from $26.4 million in 2024, primarily due to a decrease in license revenue, although milestone revenue increased, indicating the company's efforts in cost control and operational optimization.
- Future Outlook: The company expects revenue in 2026 to range from $25 million to $30 million, with operating expenses controlled between $80 million and $85 million, indicating a trajectory towards positive cash flow while continuing to invest in technological innovation and market expansion.
See More
OmniAb Reports Q4 2025 Earnings with Growth Momentum
- Partner Growth: By the end of 2025, OmniAb increased its partner count from 104 to 107 and active programs from 399 to 407, demonstrating strong momentum in expanding partnerships and projects, which is expected to support future revenue growth.
- OmniUltra Launch: The introduction of OmniUltra at the Antibody Engineering Conference, touted as the industry's first transgenic chicken platform for ultra-long CDRH3 on a human antibody framework, is anticipated to attract new partners and enhance near-term revenue opportunities, further solidifying the company's market position.
- Financial Performance: Q4 2025 total revenue was reported at $8.4 million, down from $10.8 million in the same period in 2024, primarily due to decreased license revenue, although milestone revenue increased, reflecting the company's efforts in revenue diversification.
- 2026 Outlook: The CFO projected 2026 revenue to range between $25 million and $30 million, with operating expenses expected to be between $80 million and $85 million, indicating a positive outlook for future growth while maintaining operational efficiency.
See More
OmniAb Reports Q4 Earnings Miss with Revenue Decline
- Earnings Miss: OmniAb's Q4 GAAP EPS of -$0.11 falls short by $0.02, indicating challenges in profitability that could negatively impact investor confidence.
- Revenue Decline: The company reported revenue of $8.4 million, a 22.2% year-over-year decrease, missing expectations by $0.6 million, reflecting weak market demand and increased competition that may affect future market share.
- Future Outlook: OmniAb expects 2026 revenue to range between $25 million and $30 million, with operating costs projected at $80 million to $85 million, highlighting pressure on cost control that could impact profitability.
- Cash Flow Status: The company anticipates ending the year with cash and cash equivalents between $30 million and $35 million, indicating stable cash flow; however, high operating costs may limit investment capacity and growth potential.
See More
OmniAb Launches First Transgenic Chicken Platform, Expanding Therapeutic Opportunities
- Platform Innovation: OmniAb launched the OmniUltra™ platform at the Antibody Engineering & Therapeutics Conference in San Diego, marking the industry's first transgenic chicken platform capable of expressing ultralong CDRH3 domains, significantly broadening therapeutic applications.
- Technical Advantages: The platform generates antibodies and picobodies™ with high specificity and structural stability, accelerating the drug discovery process, particularly showcasing immense potential in bispecific and multispecific drug development.
- Market Prospects: The launch of the OmniUltra platform is expected to attract strong interest from industry partners, further solidifying OmniAb's leadership in next-generation drug discovery and facilitating entry into new markets.
- Industry Engagement: OmniAb is conducting two presentations at the conference, highlighting the broad applicability of its technology and emphasizing the platform's significance in the discovery of novel mini-proteins and structured peptides, enhancing interaction with potential customers.
See More
OmniAb Reports Strong Q1 2026 Performance, Raises Revenue Guidance
- Significant Revenue Growth: OmniAb reported total revenue of $14.4 million for Q1 2026, exceeding expectations by $8.8 million, reflecting strong progress in partner programs that is expected to drive future milestones and new royalty income.
- Expanded Partner Base: As of the end of Q1, OmniAb had 107 active partners and 409 active programs, with total contracted milestones exceeding $3 billion and an average royalty rate of approximately 3.4%, laying a solid foundation for future revenue diversification.
- Upgraded Financial Outlook: The company raised its total revenue guidance for 2026 to a range of $28 million to $33 million, primarily driven by a milestone achieved by a partner that was not included in the original guidance, while maintaining cash operating expense expectations unchanged at $50 million to $55 million.
- Ongoing Clinical Progress: By the end of Q1, OmniAb had 32 active clinical programs, with Ramantamig advancing from Phase I to Phase III, demonstrating strong development potential in the clinical stage and further enhancing market competitiveness.
See More
OmniAb (OABI) Q4 2025 Earnings Call Transcript
See More
OmniAb Q4 2025 Earnings Call Highlights
- Partner Growth: By the end of 2025, OmniAb had 107 partners and 407 active programs, reflecting a net increase of 44 programs compared to 2024, demonstrating the company's ongoing expansion in its partner base and program portfolio, despite a decline in overall revenue, laying a foundation for sustained future growth.
- Innovation Platform Launch: OmniUltra, the industry's first transgenic chicken platform, was launched in December 2025, aimed at driving new partner additions and program starts, expected to generate near-term revenue opportunities and extend into peptide discovery applications.
- Financial Performance: Total revenue for 2025 was $18.4 million, down from $26.4 million in 2024, primarily due to a decrease in license revenue, although milestone revenue increased, indicating the company's efforts in cost control and operational optimization.
- Future Outlook: The company expects revenue in 2026 to range from $25 million to $30 million, with operating expenses controlled between $80 million and $85 million, indicating a trajectory towards positive cash flow while continuing to invest in technological innovation and market expansion.
See More
OmniAb Reports Q4 2025 Earnings with Growth Momentum
- Partner Growth: By the end of 2025, OmniAb increased its partner count from 104 to 107 and active programs from 399 to 407, demonstrating strong momentum in expanding partnerships and projects, which is expected to support future revenue growth.
- OmniUltra Launch: The introduction of OmniUltra at the Antibody Engineering Conference, touted as the industry's first transgenic chicken platform for ultra-long CDRH3 on a human antibody framework, is anticipated to attract new partners and enhance near-term revenue opportunities, further solidifying the company's market position.
- Financial Performance: Q4 2025 total revenue was reported at $8.4 million, down from $10.8 million in the same period in 2024, primarily due to decreased license revenue, although milestone revenue increased, reflecting the company's efforts in revenue diversification.
- 2026 Outlook: The CFO projected 2026 revenue to range between $25 million and $30 million, with operating expenses expected to be between $80 million and $85 million, indicating a positive outlook for future growth while maintaining operational efficiency.
See More
OmniAb Reports Q4 Earnings Miss with Revenue Decline
- Earnings Miss: OmniAb's Q4 GAAP EPS of -$0.11 falls short by $0.02, indicating challenges in profitability that could negatively impact investor confidence.
- Revenue Decline: The company reported revenue of $8.4 million, a 22.2% year-over-year decrease, missing expectations by $0.6 million, reflecting weak market demand and increased competition that may affect future market share.
- Future Outlook: OmniAb expects 2026 revenue to range between $25 million and $30 million, with operating costs projected at $80 million to $85 million, highlighting pressure on cost control that could impact profitability.
- Cash Flow Status: The company anticipates ending the year with cash and cash equivalents between $30 million and $35 million, indicating stable cash flow; however, high operating costs may limit investment capacity and growth potential.
See More
OmniAb Launches First Transgenic Chicken Platform, Expanding Therapeutic Opportunities
- Platform Innovation: OmniAb launched the OmniUltra™ platform at the Antibody Engineering & Therapeutics Conference in San Diego, marking the industry's first transgenic chicken platform capable of expressing ultralong CDRH3 domains, significantly broadening therapeutic applications.
- Technical Advantages: The platform generates antibodies and picobodies™ with high specificity and structural stability, accelerating the drug discovery process, particularly showcasing immense potential in bispecific and multispecific drug development.
- Market Prospects: The launch of the OmniUltra platform is expected to attract strong interest from industry partners, further solidifying OmniAb's leadership in next-generation drug discovery and facilitating entry into new markets.
- Industry Engagement: OmniAb is conducting two presentations at the conference, highlighting the broad applicability of its technology and emphasizing the platform's significance in the discovery of novel mini-proteins and structured peptides, enhancing interaction with potential customers.
See More
